Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Углх Рисерч АбfiledCriticalУглх Рисерч Аб
Priority claimed from PCT/SE2020/050381external-prioritypatent/WO2020209788A1/en
Publication of EA202192437A1publicationCriticalpatent/EA202192437A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Предложен способ восстановления органа, полученного от донора, причем орган изымают по меньшей мере через 2 ч после остановки кровообращения у донора. Способ включает введение в орган лиз-плазминогена, содержащегося в первом гиперонкотическом растворе, а затем введение тканевого активатора плазминогена (ТАП), содержащегося во втором гиперонкотическом растворе. Затем на первом этапе восстановления обеспечивают циркуляцию через орган третьей гиперонкотической жидкости, содержащей альбумин и электролиты, и на втором этапе восстановления обеспечивают циркуляцию через орган четвертой гиперонкотической жидкости, содержащей оксигенированные эритроциты. Затем оценивают орган по обычным критериям. Предложены также устройство и жидкость для использования в указанном способе.A method for restoring an organ received from a donor is proposed, wherein the organ is removed at least 2 hours after the donor's blood circulation has stopped. The method includes administering lys-plasminogen contained in the first hyperoncotic solution to the organ, and then administering tissue plasminogen activator (TPA) contained in the second hyperoncotic solution. Then, at the first recovery stage, the third hyperoncotic fluid containing albumin and electrolytes is circulated through the organ, and at the second recovery stage, the fourth hyperoncotic fluid containing oxygenated erythrocytes is circulated through the organ. The organ is then evaluated according to the usual criteria. A device and a liquid for use in said method are also provided.
EA202192437A2019-04-122020-04-12
METHOD AND DEVICE FOR RESTORATION OF ORGANS
EA202192437A1
(en)
Minimization of ischemic cholangiopathy in donation after cardiac death liver transplantation: is it thrombolytic therapy or warm ischemic time stringency and donor bile duct flush?
Debate: creating adequate pulse with a continuous flow ventricular assist device: can it be done and should it be done? Probably not, it may cause more problems than benefits!
A prospective, controlled, un-blinded, multi-center clinical trial to evaluate the thoracotomy implant technique of the HVAD system in patients with advanced heart failure: results of the LATERAL trial